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ABSTRACT
Background. Sensitive screening methods have revealed that
many patients have donor-speciﬁc human leucocyte antigen
antibodies (DSAs) prior to transplantation, regardless of
negative crossmatch results. The clinical signiﬁcance of pre-
transplant (pre-Tx) DSAs for early graft function has remained
unclear. Our aim was to examine the association of DSAs with
delayed graft function (DGF).
Methods. Pre-Tx sera of 771 patients who received kidney
transplants in our single-centre study were retrospectively
screened. All transplantations were performed after negative
complement-dependent cytotoxicity (CDC) crossmatch.
Results. DSAs were detected in 13% of the patients. The
overall DGF rate in our study was 29%. Patients with
DSAs had a higher incidence of DGF when compared
with non-sensitized patients (48 and 26%, respectively; P <
0.0001). Third-party antibodies had no effect for DGF in-
cidence (28%; P = 0.6098). The relative risk (RR) of DGF
for patients with DSAs in the multivariate analysis was
2.039 (95% CI 1.246–3.335; P = 0.0046). Analyses of the cu-
mulative mean ﬂuorescent intensity (MFI) value of the
DSAs revealed a rate of DGF more than two times higher
in patients with a cumulative value of 3000–5000 MFI com-
pared with a cumulative value of 1000–3000 (65 versus
31%; P = 0.0351). DSAs against any loci showed an elevated
DGF incidence of 44–69% when compared with patients
without DSA (27%).
Conclusions. The risk of DGF is twice as high in patients hav-
ing pre-formed DSAs. Pre-Tx DSAs is a modiﬁable risk factor
that can be obviated with careful organ allocation relying on
careful pre-Tx analysis of non-accepted mismatches deter-
mined with sensitive solid phase methods.
Keywords: delayed graft function, dialysis, donor-speciﬁc
antibody, graft survival, immunology, kidney transplantation
INTRODUCTION
In kidney transplantation (RTx) delayed graft function (DGF)
is a post-transplant form of acute renal failure that is a signiﬁ-
cant clinical problem affecting the kidney allograft for thewhole
clinical course. There are several known patient-related risk fac-
tors for DGF. These include diabetes, prolonged cold ischaemia
time (CIT), retransplantation and a high level of human leuco-
cyte antigen (HLA) antibodies [1–4]. The effect of donor death
by stroke/cerebrovascular accident, age, hemodynamic factors,
terminal creatinine and estimated glomerular ﬁltration rate are
known donor-related factors predisposing to DGF [4–8].
Patients with DGF are at risk for overall decreased graft func-
tion, acute rejection and decreased graft survival [9]. Moreover,
DGF leads to higher costs due to prolonged dialysis dependence
and hospitalization. Acceptance of expanded criteria donors
due to shortage of organs has increased the incidence of DGF
[5, 10, 11].
DGF is considered a multifactorial complication and is a re-
sult of ischaemia-reperfusion injury, where both immune and
non-immune factors play a role. It is known that presensitiza-
tion is a risk factor for DGF [2]. This may be explained in part
by longer CITs for sensitized recipients [12]. It has also been
hypothesized but not conﬁrmed that the potential immunological
mechanism could be that a low level of DSA undetected in the
crossmatch can cause an antibody-mediated rejection episode
that is interpreted as DGF [13]. Clinically, this condition may
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Recently developed solid-phase assays, especially bead-
based technology (Luminex), enables identiﬁcation of very
low levels of HLA antibodies. This has made it possible to
study the effect of well-deﬁned antibodies to transplant out-
comes. Several studies have demonstrated the role of preformed
donor-speciﬁc antibodies for rejection and graft survival [14–
16]. However, the clinical relevance of antibodies detected
with single antigen beads is still controversial and some trans-
plants may be denied based on overcautious risk estimations
[17–19]. Understanding the role of DSAs in the context of nega-
tive complement-dependent cytotoxicity (CDC) crossmatch
would be of great importance when aiming at extended graft
survival. Only limited studies have been performed to under-
stand the role of DSAs for early graft function and DGF. Earlier
studies with need for dialysis within the ﬁrst week as a deﬁnition
for DGF have been unable to identify pre-RTx DSAs as a risk
for DGF [20, 21]. We used the stricter deﬁnition of DGF by
Halloran et al. [22], which considers better clinically relevant
indicators of poor early graft function [23].
The purpose of this retrospective studywas to examine the role
of DSA status on DGF, an entity with only limited studies per-
formed with modern sensitive antibody identiﬁcation methods.
We hypothesized that pre-existing DSAs, even with a negative
prospective CDC crossmatch, possess an increased risk for DGF.
MATERIALS AND METHODS
Patients
This retrospective, single-centre study was carried out in ac-
cordance with a protocol approved by the Ethics Committee of
Helsinki University Hospital. A total of 799 consecutive adult
(≥16 years) patients received RTx during 2000–4 and were in-
cluded after written informed consent. Fifteen patients with a
living donor and 13 patients with surgical complication or ar-
terial/venal thrombosis leading to early transplantectomy were
excluded from the analysis, resulting in a total of 771 patients.
Immunosuppression
Primary immunosuppression consisted of triple therapy
based on a calcineurin inhibitor (tacrolimus or cyclosporine),
mycophenolate mofetil (MMF) and steroid. The trough level
target for cyclosporine was 150–190 μg/L and for tacrolimus
was 7–10 μg/L during the ﬁrst month. Immunologically, high-
risk patients received induction therapy (antithymocyte globu-
lin, basiliximab or daclizumab). Calcineurin inhibitor was
started prior to the transplant operation. Immunosuppression
was not adjusted according to DGF status.
Diagnostic classiﬁcations
DGF was designated if one of the following criteria was ful-
ﬁlled: (i) serum creatinine was >500 mol/L throughout the ﬁrst
perioperative week; (ii) more than one dialysis session during
the ﬁrst week after RTx and (iii) oliguria (<1 L/day) 2 days after
transplantation [22]. The conventional DGF deﬁnition (need
for dialysis during the ﬁrst week after transplantation) was used
to evaluate if the DGF deﬁnition has an impact on results. With
the conventional deﬁnition the category slow graft function (SGF)
was used (impaired creatinine clearance without need for dialysis)
[24]. Acute rejections were biopsy proven and determined accord-
ing to Banff 1997 criteria. All biopsies were performed due to clin-
ical indications, including DGF lasting over 14 days.
Donor HLA typing
TheHLA typing of the donors was initially performed with a
complement-mediated lymphocytotoxicity test (Biotest, Rock-
away, NJ, USA) and low-resolution polymerase chain reaction
with sequence-speciﬁc primer (One Lambda, Canoga Park, CA,
USA). Additional typing with polymerase chain reaction with
sequence-speciﬁc oligonucleotide (One Lambda) or sequen-
cing (Atria Genetics, South San Francisco, CA, USA) was per-
formed when the result was needed to conﬁrm donor speciﬁcity
of an antibody.
Crossmatches
CDC crossmatch was performed with gradient puriﬁed
donor spleen cells [25]. Any cell death above background was
considered positive. The test was performed at room tempera-
ture and at 37°C to eliminate autoantibodies, and it was consid-
ered positive if the positive result was detected at both
temperatures. All patients transplanted in this study had nega-
tive CDC crossmatch results.
HLA antibodies
Serum samples of the patients were collected on the day of
transplantation. The retrospective screening of HLA antibodies
was performed with Luminex-based commercial kits (LABSc-
reen®Mixed, One Lambda). Samples with detectable HLA anti-
bodies were then analyzed with LABScreen® single antigen kits
(One Lambda) to identify antibody speciﬁcities. All sera were
tested for HLA class I (HLA-A,B,Cw) and class II (HLA-DR,
DQ,DP) antibodies. Antibodies were assigned with HLA Fu-
sion™ software (One Lambda). DSAs were assigned by com-
paring assigned antibodies to the serological equivalent of the
donor’s HLA type. The strength of identiﬁed donor-speciﬁc
antibodies was determined by mean ﬂuorescent intensity
(MFI) values. Also, a low level of DSAs (<1000 MFI) was
taken into account as suggested by the analysis software, so
that the relevance of low level DSAs could be determined.
The sum value of all DSAs directed against the donor was re-
ported as a cumulative DSA. DSA identiﬁcation was done retro-
spectively, so all transplants were performed relying on the
CDC crossmatch only.
Statistical analysis
Categorical variables were analysed with the Fisher’s exact
test. Binary logistic regression analysis or Mann–Whitney
U-test was used to compare continuous variables with the pres-
ence of DGF. All results with a P-value ≤0.05 were considered
statistically signiﬁcant. All presented P-values are uncorrected
for possible multiple testing. Analyses were performed with
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A total of 771 kidney transplants from 477 deceased donors
were included in the study. The characteristics of the donors
and patients are shown in Table 1. The mean age was
46.4 ± 13.7 years, the mean donor BMI was 25.01 ± 3.88 kg/m2
and 53.0% were male. The mean age of recipients was
49.0 ± 12.2 years and 64% were male. All transplants were
ABO compatible from deceased donors. Furthermore, 10% of
the transplants were regrafts. The total incidence of DGF in
our study was 29%. The incidence of DGF was higher for re-
grafted patients (48 versus 27%, P = 0.0004) and for patients
with DSAs (48 versus 27%, P < 0.0001).
Factors associated with DGF
The multivariate analysis with binary logistic regression
analysis found ﬁve independent predictors for DGF (Table 2).
The strongest statistical association was found for donor age
[relative risk (RR) 1.037 (95% CI 1.022–1.053), P < 0.0001]
and for CIT [RR 1.068 (95% CI 1.025–1.112), P = 0.0015].
The highest relative risk was found for DSAs [RR 2.039 (95%
CI 1.246–3.335), P = 0.0046] and for patients with previous
kidney transplant [RR 1.879 (95%CI 1.064–3.319), P = 0.0297].
No association for early rejection with DGF was found [RR
0.8078 (95% CI 0.177–3.687), P = 0.7830].
HLA antibody status
Of the 771 patients, 265 (34%) had pre-existing HLA anti-
bodies. Class I antibodies were detected in 225 (29%) patients
and class II antibodies in 131 (17%). DSAs were detected in
103 (13%) patients. Class I DSAs alone were detected in
48 (6%) patients and class II DSAs in 36 (5%) and both class I
and II DSAs were detected in 19 (2%) patients. Patients with re-
transplantation had a higher DSA incidence of 53% (42/80) than
patients with the ﬁrst transplant [9% (61/691)] (P < 0.0001).
Association of antibody status to DGF
The incidence of DGF in non-sensitized and sensitized
patients was 26% (132/506) and 36% (95/265), respectively
(P = 0.0060). Patients with DSAs (n = 103) had a signiﬁcantly
higher prevalence of DGF when compared with patients with-
out DSAs (n = 668) [48 and 27%, respectively (P < 0.0001)].
Antibodies against third-party antigens had no effect on DGF
incidence (Figure 1A). The incidence of DGF was also depend-
ent on the number of antigens detected as DSAs (Figure 1B).
Patients with antibodies against a single donor antigen had a
DGF rate of 43%, whereas patients with antibodies against
two or three or more donor antigens had DGF rates of 57
and 53%, respectively (P < 0.0001). The presence of DSAs is a
risk factor for DGF in univariate analysis [RR 1.765 (95% CI
1.394–2.235), P < 0.0001]. There was no difference in CIT
between DSA− and DSA+ patients (22.2 versus 22.3 h, respect-
ively) (P = 0.8205).
The impact of DSA loci
DSAs were detected against all classical HLA loci. When
compared with the patients without DSAs (DGF rate 27%),
DSAs against any loci showed an elevated DGF incidence of
44–69%. The risk of DGF was highest in patients with DSAs
against DRB1 in the univariate analysis [RR 2.407 (95% CI
1.647–3.518), P = 0.0032; Table 3].
Association of DSA MFI values with DGF ﬁndings
To analyse the predictive value of the DSA MFI to the inci-
dence of DGF, patients with DSAs were separated into three










49 48 50 0.0348
Mean donor age, years 46 44 51 <0.0001
Male recipients, n (%) 496 (64) 344 (63) 152 (67) 0.3646
Average HLA
mismatch
2.17 2.18 2.17 0.8296
DSA positive, n (%) 103 (13) 54 (10) 49 (22) <0.0001
Transplant number, n (%)
First transplants 691 (90) 502 (92) 189 (83) Reference
Retransplants 80 (10) 42 (8) 38 (17) 0.0004
CIT, hours 22.14 21.53 23.06 <0.0001
CIT, cold ischaemia time; EF, early function; DGF, delayed graft function; HLA, human
leucocyte antigen; DSA, donor-speciﬁc HLA antibodies.
Signiﬁcant P-values are in bold.
Table 2. Factors associating with DGF: results of the multivariate logistic regression analysis
Characteristics DGF halloran Conventional IGF versus DGF Conventional IGF versus SGF + DGF
Wald RR 95% CI P-value Wald RR 95% CI P-value Wald RR 95% CI P-value
Recipient age, years 0.0306 1.001 0.987–1.016 0.8611 0.2188 0.996 0.981–1.012 0.6399 1.2120 0.992 0.979–1.006 0.2709
Recipient BMI, kg/m2 3.1528 1.047 0.995–1.102 0.0758 5.3784 1.064 1.010–1.121 0.0204 8.8660 1.076 1.025–1.129 0.0029
Diabetes 0.0371 0.963 0.654–1.418 0.8473 0.1827 0.917 0.615–1.366 0.6690 0.2219 0.917 0.640–1.314 0.6376
Re-Tx 4.7251 1.879 1.064–3.319 0.0297 4.5011 1.883 1.049–3.378 0.0339 2.0041 1.503 0.855–2.643 0.1569
Rejection ≤1 week 0.0759 0.808 0.177–3.687 0.7830 2.0819 2.932 0.680–12.637 0.1491 1.3490 2.346 0.556–9.895 0.2454
Donor age, years 23.5774 1.037 1.022–1.053 <0.0001 30.3300 1.044 1.028–1.060 <0.0001 38.1912 1.044 1.030–1.058 <0.0001
Donor BMI, kg/m2 4.5405 1.049 1.004–1.095 0.0331 5.9315 1.057 1.011–1.105 0.0149 3.5682 1.041 0.998–1.086 0.0589
CIT, hours 10.0416 1.068 1.025–1.112 0.0015 14.1251 1.085 1.040–1.132 0.0002 13.2695 1.075 1.034–1.117 0.0003
DSA 8.0462 2.039 1.246–3.335 0.0046 3.5829 1.653 0.982–2.782 0.0584 4.1837 1.668 1.022–2.723 0.0408
BMI, body mass index; Re-Tx, previous kidney transplant; CIT, cold ischaemia time; DSA, donor-speciﬁc antibody; DGF, delayed graft function; IGF, immediate graft function; SGF, slow
graft function; RR, relative risk; CI, conﬁdence interval.
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cohorts according to their cumulative DSA MFI: patients with
low DSAs (1000–3000 MFI), moderate DSAs (>3000–5000
MFI) and high DSAs (>5000 MFI). DGF status was correlated
to the DSA ﬁndings. A signiﬁcant correlation was found be-
tween DGF and the cumulative MFI value, revealing an inci-
dence of DGF more than two times higher in patients with
moderate DSAs when compared with low DSAs (65 and 31%,
respectively; P = 0.0351). Also, the risk of DGF for patients with
moderate DSAs was 2-fold higher [RR 1.9479 (95% CI 0.9822–
3.8632), P = 0.0563]. No further increase in DGF incidence was
observed in the category with high MFI (Figure 1C).
Graft outcomes
Four patients without kidney loss date were left out of the
survival analysis. Overall 5-year graft survival was 90.5%. Be-
cause the frequency of DSAs was increased in patients with
DGF, a Kaplan–Meier survival analysis was performed to ana-
lyse the effect of both DSAs and DGF on graft survival. Groups
with DGF (DSA−DGF+ and DSA+DGF+) demonstrated the
lowest 5-year graft survival (84.8 and 88.9%, respectively). In
groups without DGF (DSA−DGF− and DSA+DGF−), sur-
vival was 92.1 and 93.3%, respectively. No additive risk was
observed for DSAs in DGF+ patients (log-rank test, P = 0.306;
Figure 2).
Acute reversible rejection or acute steroid-resistant rejection
was detected in 119 patients. Rejections were detected on a me-
dian Day 20 after transplantation for patients with or without
DGF. Patients with DGF had a rejection rate of 19%, whereas
patients without DGF had rejection rate of 14% (P = 0.1004).
Patients with DGF had a higher rejection rate if DSAs were de-
tected, but this difference was not signiﬁcant [27% (13/49) and
17% (30/178), respectively (P = 0.1495)]. Patients with DGF
were more likely to undergo a biopsy during the ﬁrst periopera-
tive month (33 and 17%) as required by local protocol.
DISCUSSION
In this study we took a closer look to the role of sensitization
and its relation to DGF. It is known that higher panel reactive
F IGURE 1 : (A) Comparison of immunization status with DGF deﬁned by the Halloran et al. criteria [22] and conventional criteria [24]. (B)
Comparison of the number of DSAs with DGF incidence (P < 0.0001; Mann–Whitney U-test). (C) Comparison of the cumulative MFI value with
DGF incidence (P < 0.0001; Mann–Whitney U-test). AB−, no detected antibodies; non-DSA, antibodies against a third party; DGF, delayed graft
function; DSA, donor-speciﬁc antibody; MFI, mean ﬂuorescent intensity.
Table 3. Comparison of DGF rate and relative risk of DSAs directed against
different HLA antigens
DSA status N DGF,
n (%) RR 95% CI P-value
No DSA 668 178 (27)
HLA-A 22 10 (45) 1.569 0.979–2.513 0.0791
HLA-B 33 16 (48) 1.696 1.172–2.454 0.0144
HLA-C 26 13 (50) 1.741 1.166–2.599 0.0200
HLA-DRB1 13 9 (69) 2.407 1.647–3.518 0.0032
HLA-DRB3-5 18 8 (44) 1.528 0.901–2.592 0.1262
HLA-DQ 22 11 (50) 1.734 1.125–2.673 0.0319
HLA-DP 18 8 (44) 1.528 0.901–2.592 0.1262
Total HLA-DSA 1.785 1.406–2.266 <0.0001
HLA, human leucocyte antigen; DGF, delayed graft function; DSA, donor-speciﬁc
antibody; RR, relative risk; CI, conﬁdence interval.
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antibody values predispose to DGF, but evaluation of the
strength and speciﬁcity of these antibodies has been scarce so
far [20, 21]. This study demonstrates that HLA antibodies di-
rected against allograft are associated with a higher risk for
DGF compared with patients without HLA antibodies or
with HLA antibodies against third-party antigens. DSAs were
identiﬁed from 13% (103/771) of patients. This is in accordance
with previous ﬁndings showing the same incidence of 13% for
pre-RTx DSAs [20].
The total incidence of DGF in our study was 29% (227/
771), which corresponds to earlier ﬁndings of 24–29% [2, 4,
12, 26]. According to our study, patients with DSAs had an in-
cidence of DGF nearly twice as high as patients without third-
party antibodies or non-DSA. This contradicts a previous
study by Gupta et al. [20], where a DGF frequency of 15%
was observed for patients with DSAs and 25% for patients
without DSas or third-party antibodies [20]. Also, in a study
by Thammanichanond et al. [21], no difference in DGF rate
was observed in patients with or without DSAs. The contra-
dicting results could be explained at least partially by two fac-
tors. First, the deﬁnition for DGF was different. We used the
DGF deﬁnition of Halloran et al. [22], according to which at
least two cycles of dialysis are required for the diagnosis. In
addition, clearly elevated serum creatinine and oliguria were
regarded as clinical indications for poor graft function and
were taken into account for the deﬁnition of DGF [22]. In con-
trast, in previous studies a need for dialysis in the ﬁrst week
corresponded as a deﬁnition for DGF. However, simple need
for dialysis after transplantation may not always indicate DGF
and may originate from pre-RTx dialysis practices and ﬂuid
status or poor potassium balance after transplantation. Most
importantly, the decision on the need of dialysis is based on
the physician’s individual interpretation of the post to
operative clinical status. The ﬁndings of Jayaram et al. [23]
support this idea: only patients with DGF requiring more
than one-time dialysis had an increased risk for death, lower
renal function and higher incidence of acute rejections during
the ﬁrst perioperative year. The conventional deﬁnition of
DGF introduces an additional category of SGF. In SGF, slow
recovery of graft function is measured by an impaired decrease
in serum creatinine. The difference between SGF and DGF is
arbitrary. They both represent early graft dysfunction with the
same risk factors and outcomes [27]. This category was not
taken into account in the previous studies and may explain
our contradicting results. Indeed, our analysis revealed that
only when SGF was taken into account with the conventional
deﬁnition was an association between DSAs and impaired
graft function found in multivariate analysis. When studying
early graft function relying on the conventional deﬁnitionmay
be too simplistic to study this rather complex clinical
condition.
The sensitivity of Luminex to identify very low level anti-
HLA antibodies has raised the question regarding the cut-off
value for clinically relevant antibody levels. In our study, we
compared the cumulative MFI value of the DSAs to early
graft function and found that the MFI value of the DSAs was
a clearly signiﬁcant factor, as shown with Mann–Whitney
U-test (Figure 1). Comparison of the DSAMFI value categories
revealed that the incidence of DGF was higher in the group
with cumulative DSAs of 3000–5000 MFI versus 1000–3000
MFI (65 versus 31%), suggesting a cut-off value >3000 MFI
for clinically relevant DSA in the context of early graft func-
tion. With the standard Luminex method, identiﬁcation of
complement-ﬁxing antibodies is not possible. However, all
transplants were performed against a negative CDC cross-
match. Thus, identiﬁed DSAs were most likely either low
titre or non-complement binding. Modiﬁcation of the assay
to identify C1q binding antibodies has been reported to have
a powerful predicting value of poor graft survival in RTx
patients [28].
Traditionally the matching for organ allocation has been
based on three loci—HLA-A, -B, and DRB1—with some vari-
ation between centres. The relevance of other HLA loci has been
unclear since routine testing to identify antibodies against other
loci has not been readily available. In our study, we found that
the incidence of DGF was highest for patients with antibodies
directed to donor DRB1 (69%), suggesting the importance of
avoiding DRB1 DSAs. According to the univariate analysis,
antibodies against HLA-B, HLA-C, DRB1 and DQB1 asso-
ciated with DGF (P = 0.0144, 0.0200, 0.0032 and 0.0319, re-
spectively) and the RR for DGF is highest for patients with
DSAs directed against donor DRB1.
The importance of DGF for graft outcome has been shown
in several previous studies. The risk for acute rejection is asso-
ciated with a 38–44% relative increase for patients with DGF
[2, 9]. Khalkhali et al. [29] showed that DGF poses an in-
creased risk for death-censored graft loss (RR 6.087;
P < 0.001).
In our study, we hypothesized that pre-existing DSAs, even
with a negative prospective CDC crossmatch, poses a signiﬁcant
risk for DGF, and this might have been missed in other studies
F IGURE 2 : Graft survival for recipients with or without DSAs and
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using need for dialysis as the only criterion for DGF. This infor-
mation, when combined with the crossmatch result, would be
of great importance when aiming for safe organ allocation with
extended graft survival.
There are several limitations in our study. First, it is difﬁ-
cult to estimate the relevance of DSAs against certain loci, be-
cause DSAs were found against multiple loci in 37% of the
DSA+ cases. Second, our study was not designed to study
the capacity of complement binding of DSAs. Determing
the effect of complement-binding DSAs on DGF will require
further studies. Third, the criteria used for DGF have no time
limit when graft function must be achieved. This allows pa-
tients with primary non-function of the graft to be included
in the DGF group (these were excluded from the survival
analysis).
In conclusion, the presence of DSAs detected by Luminex is
a clear predisposing factor for DGF in our CDC crossmatch-
negative recipients. However, it is not a major factor accounting
for DGF, because the majority (78%) of the DGF was seen in
our study in patients without DSAs. DSAs are a modiﬁable
risk factor that can be considered with organ allocation for pa-
tients who are able to get a DSA-negative transplant. The pres-
ence of pretransplantation DSAs should not be used as an
absolute contraindication for transplantation. Instead, it is a
risk factor that needs to be considered critically in organ alloca-
tion schemes so that overall graft survival increases. However,
transplants against low-level DSAs with good yet moderately
decreased outcomes should be possible in highly sensitized
patients.
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